Q2
BTMD — Q2 2026 Financial Report Analysis
Biote's Q2 2026 revenue fell 9.5% to $44.2M as a pellet recall cut procedure revenue 13.9% and raised costs; $5.1M of legal settlements pushed it to a $0.23 loss per share, and full-year guidance was cut to above $175M revenue and $25M adjusted EBITDA.